Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a particularly challenging patient group. This post delves into the key aspects and outcomes of this trial, highlighting its significance in the field of oncology. … SYNC-T Technology: A Novel Approach from Syncromune® Inc. SYNC-T technology is an advanced treatment method that integrates a personalized vaccine with a multi-component biologic to target the immune system at the site of the tumor. This process involves directly injecting the tumor site, freezing part of the tumor to release antigens, and simultaneously infusing a…
Author: admin
Introduction to Emerging Therapies in ALL Management … Dr. Elias Jabbour shared recent developments in the treatment of acute lymphoblastic leukemia (ALL) during a recent medical conference. His presentation focused on the evolving landscape of ALL therapy, particularly emphasizing the growing importance of targeted therapies including bispecific antibodies, antibody-drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs). The integration of these therapies is reshaping the standard treatment protocols, potentially reducing reliance on conventional chemotherapy and transplantation. The Role of Tyrosine Kinase Inhibitors (TKIs) A significant portion of the session was dedicated to discussing the effectiveness of TKIs. Dr. Jabbour outlined the…
… The field of oncology is continuously evolving, with research focusing on developing more effective and personalized treatment modalities. One such significant stride in this direction is the KRYSTAL-1 study, which explores the efficacy and safety of combining adagrasib (MRTX849) with cetuximab in treating patients with metastatic colorectal cancer (CRC) harboring the KRASG12C mutation. This article delves into the study’s findings, its implications for clinical practice, and future research directions. Overview of the KRYSTAL-1 Study The KRYSTAL-1 study is a multicenter, phase 1/2 clinical trial that investigates the combination of adagrasib, a KRASG12C inhibitor, and cetuximab, an EGFR inhibitor, in…
… Pancreatic cancer, notorious for its lethality and late-stage diagnosis, presents significant challenges in oncological treatment and patient survival. Dr. Ajay Goel’s recent research introduces a transformative approach to early cancer detection through a blood-based liquid biopsy, leveraging microRNAs and exosomes for unparalleled accuracy. This article delves into the study’s methodology, findings, and its profound implications for the future of oncology. Early Detection: A Paradigm Shift Dr. Goel’s study addresses a critical issue in pancreatic cancer treatment—the disease’s diagnosis at an advanced stage, rendering it inoperable and drastically reducing survival chances. The research aims to circumvent this through early detection,…
… Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. The discovery of specific mutations within NSCLC, such as those in the KRAS gene, has paved the way for targeted therapies. However, tumors harboring KRAS mutations, especially those with concurrent STK11 and KEAP1 mutations, have shown a worse prognosis due to their resistance to current therapies, including chemotherapy and immunotherapy. The work of Triparna Sen, PhD, sheds light on a novel therapeutic target, Stearoyl-CoA Desaturase 1 (SCD1), which plays a pivotal role in the metabolic rewiring of…
… Multiple myeloma, an incurable cancer affecting plasma cells in the bone marrow, continues to challenge the medical community. The search for more effective treatments has led to the development of innovative therapies targeting specific mechanisms involved in cancer progression. A significant breakthrough in this quest is Linvoseltamab, a BCMA CD3 bispecific antibody, which has shown promising results in relapsed and refractory multiple myeloma patients. Sundar Jagannath, MD, presented compelling data at the AACR, highlighting the efficacy and safety of this fully human antibody, which marks a potential paradigm shift in the treatment approach to multiple myeloma. Efficacy of Linvoseltamab…
… Introduction Small cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited benefit due to the cancer’s rapid progression and recurrence. The search for more effective treatments has led to the exploration of combining traditional chemotherapies with immunotherapies to harness the body’s immune response against tumor cells. A promising development in this field is the use of Lurbinectedin, a therapy initially approved for second-line treatment of SCLC, which has shown potential in not only directly combating tumor cells but also in enhancing the efficacy of immunotherapy agents. The Mechanism of Lurbinectedin Lurbinectedin…
… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing a platform for groundbreaking research, discussions, and recognition of young talent in the field. Dr. Sumanta Kumar Pal, MD known as Monty, took a moment to reflect on the successes of this year’s summit, marking significant milestones and achievements that pave the way for future advancements in cancer research and treatment. Launch of the Young Investigator Award A highlight of MOASC 2024 was the inauguration of the Young Investigator Award, a commendable initiative sponsored by Aveo, aimed at acknowledging and…
The MOASC represents a prestigious accolade designed to recognize and encourage promising young researchers in the field of oncology. This award seeks to highlight individuals who have demonstrated exceptional potential through their innovative research, contributions to oncology, and commitment to advancing cancer care. Awardees are selected based on the novelty, impact, and scientific merit of their work, showcasing groundbreaking findings that could lead to significant advancements in the diagnosis, treatment, and understanding of cancer. The recognition not only celebrates the achievements of these emerging leaders in oncology but also aims to foster their career development, providing support and visibility within…
… At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical oncology at Cedars-Sinai, Los Angeles, CA, provided a comprehensive update on the transformative approaches in the perioperative management of non-small cell lung cancer (NSCLC). With a distinguished career marked by contributions to advancing treatment modalities, Dr. Reckamp’s insights into the integration of immunotherapy and targeted therapy in NSCLC offer valuable perspectives for oncologists navigating this evolving landscape. Oncogenic Drivers and Treatment Evolution in NSCLC The journey of NSCLC treatment has been significantly influenced by the understanding of oncogenic drivers and…
… Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T. Moyers from The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, presented a detailed update on March 6, 2024, providing oncologists with the latest data and clinical insights into melanoma management. Key Studies and Approved Treatment Combinations CHECKMATE-067: Establishing a New Standard CHECKMATE-067 compared the effectiveness of nivolumab alone, nivolumab plus ipilimumab, and ipilimumab alone in patients with unresectable stage III or IV melanoma. This trial identified the combination of nivolumab and ipilimumab as superior in terms of progression-free survival…
… The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of groundbreaking studies and novel therapeutic agents. This detailed review, drawing from a presentation by Elizabeth Brem, MD, at the University of California, Irvine, delves into the significant strides made in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) treatment. It examines pivotal trials, compares therapeutic strategies, and discusses their implications for current clinical practice, offering oncologists a roadmap for integrating these innovations into patient care. Hodgkin Lymphoma: Evolving Standards and New Horizons Revisiting ECHELON-1: A Benchmark in HL Treatment…
… Introduction to ADCs in Cancer Therapy The advent of targeted therapies has revolutionized the field of oncology, offering new hope and improved outcomes for patients with hematological malignancies. Among these innovative treatments, Antibody-Drug Conjugates (ADCs) such as Inotuzumab Ozogamicin (INO) and Gemtuzumab Ozogamicin (GO) have emerged as significant advancements. These therapies uniquely combine the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic agents, specifically targeting cancer cells while sparing healthy tissue. However, the clinical application of INO and GO has unveiled a challenging aspect of their use: liver toxicity, including sinusoidal obstruction syndrome (SOS) and thrombocytopenia. Drawing…
… In the rapidly evolving field of oncology, colorectal cancer (CRC) represents a significant area of research and clinical development. Innovations in genetic profiling and targeted therapies have led to considerable advancements in the treatment of CRC, offering new hope and improved outcomes for patients. This article, grounded in the comprehensive data presented by Heinz-Josef Lenz, MD, from the USC Center for Cancer Drug Development at the 2024 MOASC Annual Oncology Summit & Research Symposium in Newport Beach California, aims to provide oncologists with an in-depth overview of the current state and future directions in CRC treatment. [EXCLUSIVE VIDEO with…
… [VIDEO & SLIDES] Alex Chehrazi –Raffle, MD, City of Hope – 2024 MOASC Annual Oncology Summit & Research Symposium In the ever-evolving field of oncology, the management of non-metastatic prostate cancer represents a significant area of interest due to the potential for curative treatment outcomes. With advancements in diagnostic techniques and treatment modalities, the approach to treating non-metastatic prostate cancer is becoming increasingly sophisticated. This article builds upon the insights provided by Alex Chehrazi-Raffle, MD, from the City of Hope Comprehensive Cancer Center, to explore the nuanced strategies in the systemic treatment of non-metastatic prostate cancer. It covers the…
… [VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research Symposium In the rapidly advancing field of breast cancer treatment, the emphasis on personalizing therapy to individual patient needs and tumor characteristics has become increasingly paramount. Dr. Rebecca Shatsky, MD an esteemed Associate Professor of Clinical Medicine at UC San Diego, provides an in-depth exploration of the latest strategies and breakthroughs in breast cancer management at the 2024 MOASC Annual Oncology Summit & Research Symposium. This article delves into the critical aspects of her presentation, which spans the gamut from the…
Overview The U.S. Food and Drug Administration (FDA) has granted approval for the use of inotuzumab ozogamicin (Besponsa, Pfizer) in pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This decision represents a significant advancement in the treatment options available for this particular patient population. [Exclusive Video] Efficacy and Safety of Inotuzumab Ozogamicin (BESPONSA) – Mojtaba Akhtari, MD, FACP-Professor of Medicine-Loma Linda University – MOASC 2024 Advances in Oncology … Efficacy Evaluation The approval was based on data from a multicenter, single-arm, open-label study involving 53 pediatric patients aged 1 year…
On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene USA, Inc., for the treatment of relapsed or refractory follicular lymphoma (FL) following two or more lines of systemic therapy. Study Background: ROSEWOOD Trial (BGB-3111-212) The approval was based on findings from Study BGB-3111-212, also known as the ROSEWOOD trial (NCT03332017). This open-label, multicenter, randomized trial enrolled 217 adult patients with relapsed or refractory FL after at least two prior systemic treatments. Patients were randomized in a 2:1 ratio to receive either zanubrutinib 160 mg orally twice daily in combination…
The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific antibody is being evaluated for its efficacy in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy. The Importance of Priority Review Priority Review is granted by the FDA to investigational therapies that have the potential to significantly improve the safety or effectiveness of treating serious conditions compared to standard applications. This designation shortens the review period to six months, as opposed to the standard 10 months. If approved, epcoritamab-bysp (EPKINLY®)…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set of challenges for both patients and healthcare providers. Angela Fleischman, MD at Spotlight on Myelofibrosis 2024 from MOASC, focuses on the critical role of Janus kinase (JAK) inhibitors in managing this disease. Despite the common association of JAK2 V617F mutations with myeloproliferative disorders, Fleischman underscores the effectiveness of JAK inhibitors across various genetic mutations, expanding the therapeutic horizon beyond JAK-mutated patients alone. [VIDEO] 2024 Myeloproliferative Neoplasms Updates [33 SLIDES] – Angela Fleischman, MD, PhD – Spotlight on Hematology 2024 MOASC … Clinical Challenges of Myelofibrosis…
Zahra Pakbaz, MD, shed light on a range of critical findings from the American Society of Hematology (ASH) meeting, with a particular focus on the dynamic sphere of benign hematology. Amidst a potential shortfall in expertise within this field, Pakbaz’s research, conducted with a team of dedicated students, highlighted the pivotal role that hematologists play in the management of non-cancer blood disorders, such as sickle cell disease. This article delves into the significance of Non-Malignant Hematology Clinics, presenting Pakbaz’s insights on the vital presence of these clinics and the exciting potential that gene therapy holds for sickle cell disease and…
In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various forms of lymphoma. Dr. Stefan Ciurea’s comprehensive discussion at a recent medical conference highlighted the significant strides made in this innovative treatment modality, underscoring its potential and challenges. This article delves into the updates, studies, and clinical experiences shared by Dr. Ciurea, offering a detailed view for physicians engaged in the field. [69 SLIDES with VIDEO] 2024 CAR-T-cell Hematology Updates – Stefan Ciurea, MD – MOASC … Advancements in CAR T-cell Therapy for Multiple Myeloma Recent trials have showcased the…
ASH Groundbreaking Trials and Therapies Transform Multiple Myeloma Treatment The recent American Society of Hematology (ASH) meeting showcased significant advancements in multiple myeloma treatment, with a particular focus on integrating CD38 monoclonal antibodies into frontline therapy and exploring the benefits of quadruplet regimens. These developments promise to reshape patient care, offering new hope for those battling this challenging disease and were highlighted at the MOASC Spotlight on Myeloma 2024. [VIDEO with 36 SLIDES] 2024 Multiple Myeloma Updates – Lisa X. Lee, MD … The Griffin and PERSIUS Trials: A New Era in Myeloma Treatment Dr. Lisa X. Lee highlighted the…
Assessing the Impact of COVID-19 on Cancer Screening and Diagnosis Rates in the United States: A 2020 Overview The COVID-19 pandemic, emerging from the discovery of the SARS-CoV-2 virus in 2019, has led to widespread disruptions across various sectors, including healthcare. Undiagnosed Cancer & COVID-19 is one of the less visible but highly impactful disruptions has been in the field of cancer screening and diagnosis. The pandemic’s interference with routine health care and cancer screening services has led to a significant drop in cancer diagnoses across the United States. This article delves into a comprehensive analysis conducted to understand the…
March 1, 2024 – In a significant advancement for lung cancer treatment, the Food and Drug Administration (FDA) has approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed. This new therapy is designated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as confirmed by an FDA-approved diagnostic test. Traditional Approval Granted for Amivantamab-vmjw The FDA has also issued traditional approval for amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. This approval…
A New Horizon in Gene Editing In the rapidly evolving field of genetic medicine, a groundbreaking development has emerged with the introduction of a novel CRISPR-based tool, MEGA-CRISPR. This innovation promises to bring a significant transformation to cancer therapy, setting a new standard for precision medicine. Traditional CRISPR systems, known for their ability to edit DNA, have been pivotal in advancing genetic research and therapy. However, MEGA-CRISPR diverges from this path by targeting RNA instead, offering a more flexible and reversible method for modifying cellular behavior. This shift not only enhances the potential of cancer-fighting cells but also paves the…
The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with the introduction of rusfertide, a groundbreaking drug developed through the collaborative efforts of the Icahn School of Medicine at Mount Sinai. This innovative therapy has shown promising early success in clinical trials, heralding a potential paradigm shift in the management of PV, a condition that has historically been challenging to treat effectively. “Rusfertide appears to represent a significant step forward in treating polycythemia vera through its unique approach of limiting the amount of iron available for blood cell production,” states…
On February 15, 2024, the Food and Drug Administration (FDA) approved tepotinib, commercially known as Tepmetko®, for its use in adult patients with metastatic non-small cell lung (NSCLC) cancer exhibiting MET exon 14 skipping alterations. This milestone followed its previously granted accelerated approval, reflecting a substantial leap forward in precision medicine for lung cancer. Tepotinib’s Path from Accelerated to Traditional Approval Originally granted accelerated approval based on promising outcomes from the VISION trial, tepotinib’s journey to full FDA endorsement was underpinned by clinical scrutiny and an expanded dataset, affirming its role in targeting MET-dependent tumor cells in NSCLC. The European…
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews Below) On February 20th, 2024 the Teclistamab FDA approval of TECVAYLI® (teclistamab-cqyv) for biweekly dosing was announced as a significant advancement in the treatment landscape for relapsed or refractory multiple myeloma (RRMM), offering a new beacon of hope for patients battling this incurable blood cancer. This approval underscores the commitment to addressing the complex needs of patients with multiple myeloma, especially those who have shown resistance to previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Understanding Multiple…
What is the new treatment for metastatic melanoma? On February 16, 2024, the medical community witnessed a significant milestone in the fight against metastatic melanoma, a notoriously aggressive form of skin cancer responsible for a substantial number of cancer-related deaths worldwide. The Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), marking the advent of the first cell therapy for adult patients with unresectable or metastatic melanoma that have exhibited resistance to conventional treatments. This novel T cell immunotherapy, developed by Iovance Biotherapeutics, Inc., is tailored for patients who have previously undergone treatment with a PD-1 blocking antibody…
On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name Tagrisso by AstraZeneca Pharmaceuticals LP, in combination with platinum-based chemotherapy. This approval offers a new treatment avenue for adult patients battling locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by specific genetic mutations: EGFR exon 19 deletions or exon 21 L858R mutations. These mutations must be identified using an FDA-approved test, ensuring the targeted application of this therapy. The Clinical Landscape of NSCLC (Non small cell lung cancer) Non-small cell lung cancer represents a significant portion of lung…
We asked 5 top KOLS at ASCO GI 2024 the same questions on MRD and CTDNA testing. You might be surprised by the diverse answers. Investigating MRD and ctDNA Testing: Insights from Top KOLs at ASCO GI 2024 Introduction The landscape of oncology research is continually shaped by advancements in minimal residual disease (MRD) and ctDNAtesting (circulating tumor DNA), particularly in colorectal cancer. The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) serves as a pivotal platform for sharing groundbreaking research and clinical insights among oncologists and researchers. We asked five top Key Opinion Leaders (KOLs) at ASCO GI…
… Anup Kasi, MD, Associate Professor and Vice Chair of GI Oncology at the University of Kansas Medical Center, is propelling forward the battle against metastatic pancreatic cancer, shedding light on the transformative potential of targeted therapies. Among these, KRAS G12C inhibitors and protein degraders have emerged as crucial weapons in targeting the KRAS gene mutations, which are pivotal in the oncogenesis of not only pancreatic cancer but also colorectal and lung cancers. This marks a significant shift towards precision medicine, focusing on the molecular underpinnings of cancer.KRAS Gene’s Role in OncologyThe KRAS gene, a member of the mammalian Ras…
Suneel Kamath, MD: [00:00:00] So this this trial that the tech 24 trial was really looking at a pan G. I. Population evaluating tucatinib plus trastuzumab and then full fax chemotherapy across a number of different G. I. Cancer. The thing that was really the strength of it is that this is recognizing really that her to amplification is extremely important biomarker. wE first found it in breast cancer, of course, and have been using gastric cancer and esophageal cancer for many years, but we’re starting to recognize more and more that this does really have kind of a tumor…
Van K. Morris, MD: [00:00:00] Thanks Allen for for having me and letting me represent our team of investigators who reported the results from the NRG-GI005 (COBRA) trial. This past weekend at the ASCO GI Symposium in San Francisco, this is a phase two trial that evaluated the role of circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with low risk stage two eight colon cancer. This was also the first trial that the NCI ever supported evaluating circulating tumor DNA as an integral biomarker for any solid tumor type. So we all recognize that in…
Naureen Starling, MD: [00:00:00] Of course. So AZUR-2, as you said, is a global study. Open label, randomized, running in over 245 centers in over 26 countries globally. So a global study and patients. So 711 participants will be recruited with DMMR or MSI high. Resectable colon cancer stay with a clinical stage of T four N zero or stage three. And that’s by clinical staging. And participants will be randomized on a two to one basis between the experimental arm versus the control arm. And in the experimental arm, participants randomized to that arm will have neoadjuvant doss, which…
Sakti Chakrabarti, MD: [00:00:00] So Dream GI is a national database through which we collect data on localized GI cancer patients who have MSI high tumors and who have received immunotherapy up front. We also call it new adjuvant immunotherapy. The idea behind this database is that new adjuvant immunotherapy is being given to patients who have localized GI cancers and MSI high tumor, right now, outside of a clinical trial, because many of these patients are not good surgical candidates. If those patients are getting the treatment, it makes a lot of sense to collect that data and analyze…
Michael Weickert, PhD: [00:00:00] So the first thing I want to explain is Zelenirstat is a first in class therapy targeting a new target that’s never been drugged before for any indication. So this is the first time it’s been studied in patients and we do what’s called a phase one study which is primarily to identify safety. Is it safe to dose this new drug which has never been dosed before at a new target that’s never been drugged before? So our study was designed to escalate the dose gradually in a series of patients that are not selected…
Thejus Jayakrishnan, MD: [00:00:00] Those of you who have listened to the keynote address today by Dr. Ng from Dana Farber, she highlighted how there is an increasing incidence of early onset GI cancers. In fact, we’re seeing more and more young patients Young people developing cancers and the largest increase is happening in GI cancers and specifically in cholangiocarcinoma. So over the years we’ve seen more and more patients dying from cholangiocarcinoma and we do not know what is the reason for this and we also don’t know are there any features that are unique to young patients compared…
Sawyer Bawek, MD: So in colorectal cancer with liver metastasis, studies have shown that immunotherapy has a poor response on those patient populations. So what we wanted to do is one look at the role of immunotherapy and gastroesophageal cancer in patients with liver metastasis and see if it also has a poor response. So we looked at all phase three. randomized controlled trials looking at immunotherapy um, in advanced metastatic gastroesophageal cancer. And after analyzing all the studies, we found about seven studies that had data on overall survival and progress and free, progression free survival with liver metastasis.…
Anup Kasi, MD: [00:00:00] So this is an investigative initiated trial called the EPIC trial. Where we’re investigating n fotamibidotin, which is an antibody drug conjugate as a single arm, non randomized. Phase two study a single institution study at our site at University of Kansas in patients with advanced pancreatic cancer in the second line and beyond setting. As a phase two study, this primary objective of this study is looking at the objective response rate. And then we do have some secondary objectives such as OS, PFS, and safety analysis as well. OncologyTube: Given the aberrant overexpression of…
Simron Singh, MD: [00:00:00] So radioligand therapy is like in a new emerging treatment for cancer. where we try to inject radioactive isotopes through the body that bind to the cancer receptors and are taken up by the cancer cells and then the cancer cells are killed, but generally preserve healthy tissue. So the NETTER-2 clinical trial is the first clinical trial to date that examines this type of therapy as the first line therapy in any cancer. And so specifically with the NETTER-2 trial, we looked at advanced Grade two and grade three neuroendocrine cancers from the G. I. Tracked…
Howard S. Hochster, MD: [00:00:00] Um, first of all, this is for late line colorectal cancer after the standard chemotherapy and targeted therapy drugs. it’s a space where we’re seeing new drugs approved for colon cancer, but many people continue to have the need for additional treatments once they finish the approved drugs. this particular drug is quite novel, ME344. we are working, in the, AGIC group, the Academic GI Cancer Consortiwhich is an academically based Phase II national consortium. with MEI Pharma to test this drug. It’s novel because it interrupts mitochondr m my this is novel because it,…
OncologyTube: [00:00:00] Okay. We’re here at ASCO GI 2024. And, we have the honor of, having Dr. Christopher Lieu, MD medical doctor, associate director for clinical research, co director gastrointestinal medical oncology at University of Colorado and Aurora, Colorado. Dr. Lu, thank you so much for joining us. Well, thank you for having me. Okay, today we’ll be discussing the NRG-GI008 colon adjuvant chemotherapy based on evaluation of a residual disease otherwise known as the circulate North America trial, which is featured here at ASCO GI 2024. So Dr. Liu, can you provide an overview of the NRG G. I. …
OncologyTube: [00:00:00] Okay, here we are at ASCO GI 2024. We have Dominik Paul Modest, MD medical doctor from Charite,University of Medicine in Berlin. Dr. Modest, thank you so much for joining us today. You’re welcome. Today, we’ll be discussing health related quality of life in patients with metastatic colorectal cancer treated with sotorasib and panitumumab versus Trifluoridine, Tirapercel and regorafenib in Codebreak300, which is featured here at ASCO GI 2024. Dr. Matas, can you provide an overview of the Codebreak300 trial? Dominik Paul Modest, MD: Sure. Um, it’s a spectacular trial in a way because it’s three arm in…
OncologyTube: [00:00:00] Okay. Okay, we’re here at ASCO GI 2024 and we have Dr. Anthony B. El-Khoueiry, MD a medical doctor, associate professor of medicine at USC Norris Comprehensive Cancer Center, USC, in Los Angeles. Dr. El Khoury, thank you so much for joining us today. Pleasure. Okay. Today we’ll be discussing Tizolizumab plus chemotherapy with or without Bevacizumab and advanced biliary tract cancer results from a randomized proof of concept phase two trial, otherwise known as the IMBRAVE151, which has been featured here at ASCO GI 2024. So Dr. Okahiri, can you provide an overview of the IMBRAVE151 study…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Dr. Riccardo Lencioni, MD medical doctor, professor of radiology and director of cancer imaging program at the Pisa University School of Medicine in Italy. Dr. Lencioni, thank you so much for joining us. My pleasure. Today we’ll be discussing the Emerald 1, a phase 3 randomized placebo controlled study of tastes combined with Dorvalumab with or without Bevacizumab in patients with unresectable hepatocellular cancer. carcinoma eligible for embolization, which is featured here at ASCO GI 2024. Dr. Lencioni, can you provide the overview for the Emerald One…
OncologyTube: [00:00:00] We have Dr. Milind Javle, MD. He is from the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Thank you for joining Milind Javle, MD: us today. So I’m very excited to be here and discuss a phase 3 trial that has just been initiated in FGFR altered cholangiocarcinoma. To give you a background, FGFR altered cholangiocarcinoma can be treated now with Pemigatneb. Uh, and furibatinib. These are, uh, agents that are FDA approved. Unfortunately, resistance inevitably occurs, and this occurs after six to eight months, and after that,…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Jeanne Tie, MD a medical doctor, the medical oncology lead for the lower GI tumor stream at Peter MacCallum Cancer Center and senior research fellow within the Division of Personalized Oncology at the Walter and Eliza Hall Institute in Australia. Dr. Tie, thank you so much for joining us today. Jeanne Tie, MD: You’re welcome. Pleasure to OncologyTube: be here. Today we’ll be discussing circulating tumor DNA analysis informing adjuvant chemotherapy and locally advanced rectal cancer. The randomized AGI TG dynamic rectal study, which is being highlighted here…
OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Ghassan K. Abou-Alfa, MD, medical doctor from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York. Dr. Abu Alfa, thank you so much for joining us today. Ghassan K. Abou-Alfa, MD: Thanks so much, Alan. Nice to be OncologyTube: here. Today, we’ll be discussing PROOF 301, results of an early discontinued randomized phase three trial. Dr. Abu Alfa, could you please provide an overview of the PROOF 301 Ghassan K. Abou-Alfa, MD: study? Well, thanks so much, Alan, and, uh, by all means,…